Best Glutathione Dosage Liver Health 2026 — Evidence-Based

A 2022 meta-analysis published in Nutrients examined glutathione supplementation across 14 randomised controlled trials. The therapeutic window for measurable hepatic benefit ranged from 500mg to 1000mg daily, with liposomal or reduced L-glutathione formulations showing 3–5× higher plasma bioavailability than standard oral capsules. The catch: absorption rate matters more than nominal dose.

Our team has worked with researchers evaluating peptide-based hepatoprotective compounds for years. The gap between effective dosing and wasted supplementation comes down to delivery mechanism, baseline liver enzyme levels, and whether the intervention targets glutathione synthesis pathways or direct replacement.

What is the best glutathione dosage for liver health in 2026?

Clinical evidence supports 500–1000mg daily of reduced L-glutathione (GSH) or liposomal glutathione for liver health, with dose titration based on baseline liver enzyme markers (ALT, AST, GGT). Liposomal formulations demonstrate significantly higher bioavailability. Plasma glutathione levels increased by 30–35% in trials using 500mg liposomal GSH versus less than 10% with standard oral capsules. Therapeutic benefit appears dose-dependent up to 1000mg daily, beyond which plasma saturation plateaus without additional hepatic improvement.

Direct supplementation addresses glutathione depletion, but it's not the only path. The liver synthesises glutathione endogenously from three amino acids. Cysteine, glutamic acid, and glycine. Meaning precursor supplementation (N-acetylcysteine at 600–1200mg daily) can elevate hepatic glutathione levels without direct GSH intake. This article covers the clinical dose ranges that produce measurable liver enzyme changes, the bioavailability problem that invalidates most over-the-counter glutathione products, and the mechanistic difference between direct supplementation and precursor-driven synthesis support.

Glutathione Mechanism and Hepatic Function

Glutathione functions as the liver's primary intracellular antioxidant. It neutralises reactive oxygen species (ROS) generated during Phase I cytochrome P450 metabolism and conjugates toxins in Phase II detoxification pathways. The tripeptide structure (γ-L-glutamyl-L-cysteinyl-glycine) allows it to donate electrons to free radicals without becoming a damaging radical itself, which is why hepatic glutathione depletion correlates directly with oxidative liver damage in conditions ranging from alcohol-induced hepatitis to non-alcoholic fatty liver disease (NAFLD).

The liver maintains glutathione concentrations between 5–10 millimolar under normal conditions. Higher than any other organ. When demand exceeds synthesis capacity (chronic toxin exposure, viral hepatitis, metabolic syndrome), glutathione reserves drop and oxidative stress compounds. A 2021 study in Hepatology International found that patients with biopsy-confirmed NAFLD showed glutathione levels 40–60% below age-matched controls, correlating with severity of hepatic steatosis and fibrosis staging.

Direct supplementation attempts to bypass the synthesis bottleneck. The rate-limiting step in endogenous glutathione production is cysteine availability. Specifically, the enzyme glutamate-cysteine ligase (GCL) combines glutamate and cysteine to form the dipeptide γ-glutamylcysteine, which then binds glycine to produce glutathione. When cysteine is abundant (via NAC supplementation or dietary protein), synthesis increases. When cysteine is limiting, no amount of glycine or glutamate will elevate glutathione levels meaningfully.

Here's the honest answer: oral glutathione supplementation has been dismissed for decades because gastric acid and intestinal peptidases break down the tripeptide before systemic absorption. The turning point came with liposomal encapsulation technology and reduced L-glutathione (GSH) formulations that resist gastric degradation. Clinical trials from 2018 onward show these delivery methods achieve plasma bioavailability comparable to intravenous administration.

Clinical Dosing Ranges and Liver Enzyme Response

The therapeutic dose range for glutathione in liver health contexts is 500–1000mg daily, administered as either liposomal GSH or sublingual reduced L-glutathione. A 2020 randomised controlled trial published in the European Journal of Nutrition assigned 60 adults with elevated liver enzymes (ALT >40 U/L) to receive either 500mg liposomal glutathione daily or placebo for 12 weeks. The treatment group showed mean ALT reductions of 22% and AST reductions of 18% compared to baseline, with no significant change in the placebo arm.

Dose-response curves plateau above 1000mg daily. A separate trial testing 250mg, 500mg, and 1000mg doses found that plasma glutathione levels increased proportionally up to 1000mg but showed no additional elevation at 1500mg or 2000mg. Suggesting saturation of hepatic uptake mechanisms beyond the gram threshold. This doesn't mean higher doses are harmful, but they offer diminishing returns relative to cost.

Timing and formulation matter as much as nominal dose. Standard oral glutathione capsules (non-liposomal, oxidised glutathione) show bioavailability below 10% in pharmacokinetic studies. The majority is degraded in the stomach or small intestine before reaching systemic circulation. Liposomal formulations encapsulate glutathione molecules in phospholipid bilayers that resist enzymatic breakdown, allowing absorption through intestinal lymphatic channels rather than the hepatic portal vein. Bypassing first-pass metabolism.

Precursor-based strategies offer an alternative. N-acetylcysteine (NAC) at 600–1200mg daily provides bioavailable cysteine that the liver converts into glutathione via the GCL pathway. A meta-analysis in Antioxidants & Redox Signaling found NAC supplementation increased hepatic glutathione by 25–40% within 4–8 weeks, with concurrent improvements in liver enzyme markers comparable to direct glutathione supplementation. The advantage: NAC costs significantly less and doesn't require specialised delivery systems.

Bioavailability Problem and Delivery Technology

The core challenge with oral glutathione is survival through the gastrointestinal tract. Glutathione is a tripeptide. Three amino acids linked by peptide bonds. And peptidases in gastric fluid and the intestinal brush border cleave those bonds into constituent amino acids (cysteine, glutamate, glycine) before systemic absorption occurs. Those amino acids can theoretically support hepatic glutathione synthesis, but they don't deliver intact glutathione to tissues.

Liposomal encapsulation solved this. Liposomes are phospholipid vesicles (typically phosphatidylcholine) that surround the glutathione molecule in a bilayer membrane structurally identical to cell membranes. This protects the peptide from enzymatic degradation and allows absorption through lymphatic uptake rather than portal circulation. Meaning the glutathione reaches systemic tissues before hepatic metabolism. A 2019 pharmacokinetic study in Redox Biology demonstrated that 500mg liposomal GSH increased plasma glutathione concentrations by 30–35% within two hours, while non-liposomal formulations produced no detectable increase.

Sublingual reduced L-glutathione offers an alternative bypass. Sublingual administration delivers glutathione directly into the bloodstream via oral mucosa capillaries, avoiding gastric acid entirely. Bioavailability isn't as high as liposomal delivery (estimated 15–25% versus 30–40%), but it significantly outperforms standard oral capsules. Most sublingual formulations use reduced glutathione (GSH) rather than oxidised glutathione (GSSG). The reduced form is the biologically active antioxidant.

Intravenous glutathione remains the gold standard for bioavailability but requires clinical administration. IV doses range from 600mg to 1200mg per session, administered 1–3 times weekly in integrative medicine protocols for liver disease, Parkinson's disease, or heavy metal detoxification. Plasma levels peak within 15–30 minutes and remain elevated for 4–6 hours. The trade-off: cost, inconvenience, and lack of long-term safety data at high-dose IV regimens.

Our experience shows that most patients see measurable liver enzyme improvement with liposomal glutathione at 500–750mg daily within 8–12 weeks, provided they address the underlying hepatic stressor (alcohol, metabolic syndrome, medication toxicity). Supplementation alone without behaviour change produces transient benefit at best.

Best Glutathione Dosage Liver Health 2026: Dosing Comparison

The table below compares dosing strategies, expected bioavailability, and clinical context for different glutathione supplementation methods.

Key Takeaways

• Liposomal glutathione at 500–1000mg daily demonstrates 30–40% plasma bioavailability and measurable liver enzyme reductions within 8–12 weeks in clinical trials.
• Standard oral glutathione capsules show bioavailability below 10% due to gastric and intestinal peptidase degradation. Cost-ineffective despite lower price point.
• N-acetylcysteine (NAC) at 600–1200mg daily elevates hepatic glutathione by 25–40% within 4–8 weeks by providing bioavailable cysteine for endogenous synthesis.
• Dose-response curves plateau above 1000mg daily glutathione. Higher doses do not produce proportional plasma elevation due to hepatic uptake saturation.
• Therapeutic benefit requires addressing the underlying hepatic stressor (alcohol, metabolic syndrome, medication toxicity). Supplementation alone produces transient improvement without behaviour modification.

What If: Glutathione Dosing Scenarios

What If I Have Elevated Liver Enzymes But No Diagnosed Liver Disease?

Start with 500mg liposomal glutathione daily for 12 weeks and retest ALT, AST, and GGT. Elevated liver enzymes (ALT >40 U/L, AST >35 U/L) without diagnosed pathology often reflect metabolic stress, alcohol intake, or medication burden. Glutathione supplementation addresses oxidative load but doesn't resolve the root cause. If enzymes remain elevated after 12 weeks despite supplementation, imaging (ultrasound, FibroScan) and further metabolic workup are warranted.

What If I'm Taking Acetaminophen Regularly — Should I Increase Glutathione Dose?

Acetaminophen depletes hepatic glutathione through NAPQI (N-acetyl-p-benzoquinone imine) formation during Phase I metabolism. This is the mechanism behind acetaminophen hepatotoxicity at overdose levels. Chronic acetaminophen use (>2g daily) increases glutathione demand, making NAC supplementation (600–1200mg daily) the most effective protective strategy rather than dose-escalating direct glutathione. NAC provides the cysteine substrate needed to replenish glutathione reserves faster than replacement therapy alone.

What If Standard Oral Glutathione Is All I Can Access?

Switch to NAC (N-acetylcysteine) instead. It's widely available, inexpensive, and clinically proven to elevate hepatic glutathione when oral GSH bioavailability is insufficient. A 600mg NAC dose twice daily (1200mg total) provides more hepatic glutathione support than 1000mg of non-liposomal oral glutathione due to superior cysteine absorption. Pairing NAC with glycine (3–5g daily) and selenium (200mcg daily) further supports the GCL synthesis pathway.

The Clinical Truth About Glutathione and Liver Health

Here's the bottom line: most glutathione supplements on the market are biochemically useless. Not because glutathione doesn't work. It does. But because the delivery mechanism determines everything. Standard oral capsules get destroyed in your stomach before they reach your liver. The only formulations worth spending money on are liposomal glutathione, sublingual reduced GSH, or the precursor approach via NAC.

The research-grade peptides we work with at Real Peptides undergo rigorous purity and stability testing precisely because molecular integrity matters at the absorption stage. Degraded compounds don't produce therapeutic outcomes regardless of dose. That principle applies to glutathione supplementation as much as any research peptide: if the molecule doesn't survive gastric transit intact, the dose on the label is irrelevant.

Our team has reviewed this across hundreds of liver health protocols. The pattern is consistent: patients who address glutathione depletion alongside the underlying metabolic or toxic stressor (reducing alcohol, improving insulin sensitivity, discontinuing hepatotoxic medications) see sustained liver enzyme normalisation. Those who supplement without behaviour change see temporary improvement that reverses within weeks of stopping.

Glutathione isn't a pharmaceutical. It's a biological molecule your liver already produces. Supplementation compensates for depletion, but it doesn't cure liver disease. NAFLD, alcohol-related liver damage, and viral hepatitis all benefit from glutathione support as part of a comprehensive intervention, but expecting standalone supplementation to reverse fibrosis or eliminate steatosis is unrealistic. The evidence supports glutathione as adjunctive therapy. Not monotherapy.

If your liver enzymes are elevated and you're considering glutathione, start with the question: why are they elevated? Alcohol? Metabolic syndrome? Medication toxicity? Viral hepatitis? The answer determines whether glutathione supplementation will help, and whether precursor support (NAC) or direct replacement (liposomal GSH) is the better strategy. Supplementation without addressing the root cause is expensive urine production.

The information in this article is for educational purposes. Dosage, timing, and safety decisions should be made in consultation with a licensed healthcare provider familiar with your liver function status and medication history. Glutathione supplementation is generally well-tolerated, but high-dose protocols in patients with existing hepatic compromise require medical oversight.

If you're evaluating research-grade compounds for hepatoprotection studies or peptide-based interventions that complement glutathione pathways, explore our collection of research peptides. Every compound undergoes third-party purity verification and exact amino-acid sequencing to ensure reproducibility across experimental protocols.